The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Professional Services Scientific, Architectural And Engineering Technical Activities Scientific Research And Development 72 - Scientific research and development
500 jobs Number of planned job losses
Announcement Date
12 May 2011
Employment effect (start)
Foreseen end date
Description
Pharmaceutical company MSD-Organon (formally known as Organon) is to cut over 500 jobs in its R&D division in Oss. MSD initially planned to cut more than one thousand cuts. After a year of negotiations the company has reached an agreement with the works council on the reorganisation plan, called "Plan B". The plan envisages fewer job cuts than originally planned and the creation of a new drug development centre for emerging markets (i.e. China and India). MSD is a branch of the American Merck & Co.
Sources
13 May 2011: De Telegraaf
Citation
Eurofound (2011), MSD-Organon, Internal restructuring in Netherlands, factsheet number 72025, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/72025.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
